Serelaxin: A Novel Therapeutic for Vascular Diseases Article

Leo, CH, Jelinic, M, Ng, HH et al. (2016). Serelaxin: A Novel Therapeutic for Vascular Diseases . TRENDS IN PHARMACOLOGICAL SCIENCES, 37(6), 498-507. 10.1016/j.tips.2016.04.001

cited authors

  • Leo, CH; Jelinic, M; Ng, HH; Tare, M; Parry, LJ

authors

abstract

  • Vascular dysfunction is an important hallmark of cardiovascular disease. It is characterized by increased sensitivity to vasoconstrictors, decreases in the endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH). Serelaxin (recombinant human relaxin) has gained considerable attention as a new vasoactive drug, largely through its beneficial therapeutic effects in acute heart failure. In this review we first describe the contribution of endogenous relaxin to vascular homeostasis. We then provide a comprehensive overview of the novel mechanisms of serelaxin action in blood vessels that differentiate it from other vasodilator drugs and explain how this peptide could be used more widely as a therapeutic to alleviate vascular dysfunction in several cardiovascular diseases.

publication date

  • June 1, 2016

published in

Digital Object Identifier (DOI)

start page

  • 498

end page

  • 507

volume

  • 37

issue

  • 6